Last reviewed · How we verify
A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%
The purpose of this study is to evaluate the Plasma Pharmacokinetics and Safety of AC 170 0.24% in Healthy, Adult Subjects when used twice daily for one week.
Details
| Lead sponsor | Aciex Therapeutics, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 11 |
| Start date | 2014-06 |
| Completion | 2014-08 |
Conditions
- Healthy
Interventions
- AC 170 0.24%
Primary outcomes
- Cmax values of AC 170 0.24% — 1 week
Plasma samples will be drawn at specified time points and then analyzed to determine Cmax values of AC 170 0.24% in the plasma - Tmax values of AC 170 0.24% — 1 week
Plasma samples will be drawn at specified time points and then analyzed to determine Tmax values of AC 170 0.24% in the plasma - AUC values of AC 170 0324% — 1 week
Plasma samples will be drawn at specified time points and then analyzed to determine AUC values of AC 170 0.24% in the plasma - T 1/2 values of AC 170 0.24% — 1 week
Plasma samples will be drawn at specified time points and then analyzed to determine T 1/2 values of AC 170 0.24% in the plasma
Countries
United States